Comparative Pharmacology
Head-to-head clinical analysis: BANZEL versus CEREBYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BANZEL versus CEREBYX.
BANZEL vs CEREBYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
None Documented
None Documented
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Category C
Category C
Anticonvulsant
Anticonvulsant